Vanguard Global Advisers’s Century Therapeutics IPSC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$77.3K Buy
45,218
+602
+1% +$1.23K ﹤0.01% 2885
2026
Q2
$109K Hold
44,616
– – ﹤0.01% 2735
2026
Q1
$101K Buy
+44,616
New +$93.8K ﹤0.01% 2723

Other funds holding IPSC

Vanguard Global Advisers's IPSC Position: Q3 2026 in Review

Vanguard Global Advisers increased its Century Therapeutics (IPSC) stake by 1.3% in Q3 2026, buying an estimated $1.23K and bringing the position to 45,218 shares worth $77.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2885.

Vanguard Global Advisers first reported a position in IPSC in Q1 2026 and has held it in 3 quarters since. The position peaked at $109K in Q2 2026. 102 funds tracked by Wall St. Rank hold IPSC as of Q3 2026.

  • Vanguard Global Advisers held 45,218 shares of Century Therapeutics worth $77.3K as of Q3 2026.
  • Vanguard Global Advisers bought 602 Century Therapeutics shares in Q3 2026, an estimated $1.23K.
  • Century Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2885 holding.
  • Vanguard Global Advisers first reported a position in Century Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Century Therapeutics position peaked at $109K in Q2 2026.
  • 102 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.